ARGX (argenx SE): Clear Entry Signals Emerge After Analyst Upgrade Wave

News Sentiment Analysis

Recent headlines reveal overwhelming institutional confidence in argenx. Within the last five days alone, five major firms have raised price targets - Piper Sandler to $930, TD Cowen to a striking $1,146, and RBC Capital to $860. These aren't minor tweaks; Cowen's target represents a 37% upside from current levels. The catalyst? Last week's Q3 report showing $1.13 billion in product sales and promising clinical data for VYVGART across multiple myasthenia gravis subtypes. While news volume remains moderate (7 items in 5 days), the upgrade cluster carries tangible weight - this isn't speculative chatter but concrete valuation shifts from deep-dive analysts.

Price Action Review

The chart tells a story of resilience turning into momentum. After bottoming near $631 in mid-August, ARGX staged a methodical recovery through September. The real shift came October 16-17: massive volume surges (925k shares on Oct 30 vs 377k average) propelled the stock through $800 resistance. Yesterday's action confirms strength - opening at $824.70 and climbing to $850.66 before settling at $837.57. Note how the stock consistently defends the $820-825 zone (tested 4x since Oct 22), creating a natural support floor. Volume patterns show buyers aggressively stepping in during dips - yesterday's 163k share volume was actually below recent averages, suggesting calm conviction rather than panic buying.

Predictive Outlook

Near-term trajectory looks constructive but not explosive. AI models project modest daily gains (0.8% → 0.5% → 0.8% over three days), aligning with technical patterns showing the stock in "consolidation mode" after its sharp October run. Key validation comes from the MACD crossing bullish on October 15 and holding - this isn't a fresh signal but sustained momentum. The real test arrives this week: breaking above $855.46 (52-week high) would open room toward $873, but failure could trigger profit-taking back to $825 support. Watch Tuesday's open carefully - pre-market reaction to today's Piper Sandler upgrade will set the tone.

Strategic Recommendations

Entry Strategy:

• Primary zone: $821.83-$825.87 (tested 6x since Oct 22 with strong rebound each time)
• Ideal trigger: Any dip below $825 with volume under 300k shares (indicates shakeout before rebound)

Risk Management:

• Hard stop: $744.22 (below October's swing low and 10% below entry)
• Trailing stop: Move to $825 after first 3% gain

Exit Targets:

• First take-profit: $846.48 (AI-predicted near-term ceiling)
• Final target: $872.96 (aligns with TD Cowen's target zone)

Critical Watchpoints:

• This Wednesday: FDA meeting on seronegative gMG applications (potential catalyst)
• Volume threshold: Sustained daily volume under 200k = weakening momentum

*This setup suits growth